openPR Logo
Press release

Ataxia Telangiectasia Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Companies

08-04-2022 09:45 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Ataxia Telangiectasia Therapeutic Pipeline

Ataxia Telangiectasia Therapeutic Pipeline

"Ataxia Telangiectasia Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Ataxia Telangiectasia Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Download the Sample PDF:
https://www.delveinsight.com/report-store/ataxia-telangiectasia-at-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Ataxia Telangiectasia Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Ataxia Telangiectasia Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ataxia Telangiectasia treatment.
Ataxia Telangiectasia key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Ataxia Telangiectasia Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ataxia Telangiectasia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF:
https://www.delveinsight.com/report-store/ataxia-telangiectasia-at-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Ataxia Telangiectasia Therapeutics Analysis
There are approx. 5+ key companies which are developing therapies for Ataxia Telangiectasia. Matrix Biomed has its Ataxia Telangiectasia drug candidates in the most advanced stage, i.e. phase II /III of development.

Some of the key companies in the Ataxia Telangiectasia Market include:
• Matrix Biomed
• IntraBio Inc
• EryDel
• Acasti Pharma
And many others

Ataxia Telangiectasia Therapies covered in the report include:
• MBM-01: Matrix Biomed
• IB-1001: IntraBio Inc
And many more

DelveInsight's Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Ataxia Telangiectasia Current Treatment Patterns
4. Ataxia Telangiectasia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Ataxia Telangiectasia Late Stage Products (Phase-III)
7. Ataxia Telangiectasia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Ataxia Telangiectasia Discontinued Products
13. Ataxia Telangiectasia Product Profiles
14. Ataxia Telangiectasia Key Companies
15. Ataxia Telangiectasia Key Products
16. Dormant and Discontinued Products
17. Ataxia Telangiectasia Unmet Needs
18. Ataxia Telangiectasia Future Perspectives
19. Ataxia Telangiectasia Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at:
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/ataxia-telangiectasia-at-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ataxia Telangiectasia Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Companies here

News-ID: 2697696 • Views:

More Releases from DelveInsight Business Research

Vitiligo Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech
Vitiligo Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Preva …
(Albany, USA) DelveInsight's "Vitiligo Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Vitiligo, historical and forecasted epidemiology as well as the Vitiligo market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Vitiligo market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vitiligo pipeline products will significantly
Benign Prostatic Hyperplasia Treatment Market 2032: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma,
Benign Prostatic Hyperplasia Treatment Market 2032: FDA Approvals, Clinical tria …
(Albany. USA) DelveInsight's "Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Benign Prostatic Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Benign Prostatic
Leukocyte Adhesion Deficiency Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | Rocket Pharmaceuticals, Inc., Orpha Labs
Leukocyte Adhesion Deficiency Treatment Market 2034: FDA Approvals, Clinical tri …
(Albany, USA) DelveInsight's "Leukocyte Adhesion Deficiency Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Leukocyte Adhesion Deficiency, historical and forecasted epidemiology as well as the Leukocyte Adhesion Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Leukocyte Adhesion Deficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore,
Staphylococcus aureus Bacteremia Treatment Market 2032: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | Basilea Pharma, Armata Pharma, Destiny Pharma
Staphylococcus aureus Bacteremia Treatment Market 2032: FDA Approvals, Clinical …
(Albany, USA) DelveInsight's "Staphylococcus aureus Bacteremia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Staphylococcus aureus Bacteremia, historical and forecasted epidemiology as well as the Staphylococcus aureus Bacteremia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Staphylococcus aureus Bacteremia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore,

All 5 Releases


More Releases for Ataxia

Ataxia Therapeutics Pipeline Analysis 2018 | Reata Pharmaceuticals, Inc., Voyage …
Ataxia is a type of movement disorder characterized by lack of muscle control or coordination of voluntary movements. Some of the symptoms observed in the patients with ataxia are poor coordination, change in speech, difficulty in swallowing, and unsteady walk. Download the sample report @ https://www.pharmaproff.com/request-sample/1078 The disease causes include head injury; stroke; autoimmune diseases, such as sarcoidosis and multiple sclerosis; paraneoplastic syndromes; and viral infections. The disease is also found in
Ataxia Market: Surge in Alcohol Abuse and Sedentary Life Style Bolsters the Atax …
The United States of America is marred by ataxia as more than 150,000 cases have been found in the U.S.  The surge in the ataxia cases can be attributed to the food habits and the sedentary life style. Deficiency of vitamin B-12 is termed as one of the prominent causes of ataxia. Further, slurred speech, nystagmus (involuntary back and forth eye movement), problem in eating and writing, difficulty walking and
Friedreich's Ataxia Therapeutics - Pipeline Analysis, Clinical Trials & Results, …
the Friedreich's ataxia therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Friedreich’s ataxia is an autosomal recessive inherited genetic disorder that progressively damages the nervous system. Its initial symptoms include ataxia, impaired muscle coordination and impaired speech. This results in development of dysarthria, scoliosis, heart diseases and diabetes, but does not affect cognitive function. According to the research findings, most of the drug candidates in Friedreich's ataxia
Friedreich Ataxia (Central Nervous System) pipeline landscape H-1 (2017) - MRH
Friedreich ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness, and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1063542 Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H1
Global Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Mar …
The Syndromes Progressive Ataxia Weakness Disorders Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Ataxia is a neurological condition, characterized by lack of voluntary coordination of muscle movement. Ataxia causes head trauma, stroke, Transient Ischemic Attack (TIA), tumor and toxic reaction. Progressive
Discover the Global Cerebellar Ataxia Clinical Trials Review, H2, 2016
MarketResearchReports.Biz presents this most up-to-date research on “ Cerebellar Ataxia Global Clinical Trials Review, H2, 2016 ” GlobalData's clinical trial report, Cerebellar Ataxia Global Clinical Trials Review, H2, 2016" provides an overview of Cerebellar Ataxia clinical trials scenario. This report provides top line data relating to the clinical trials on Cerebellar Ataxia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The